These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22154221)

  • 1. Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea.
    Sung YK; Cho SK; Choi CB; Park SY; Shim J; Ahn JK; Bang SY; Cha HS; Choe JY; Chung WT; Her M; Hong SJ; Hong YK; Joung CI; Jun JB; Jung YO; Kang YM; Kim DY; Kim HR; Kim HA; Kim J; Kim SK; Kim SI; Kim TH; Kim TJ; Koh E; Lee CK; Lee HS; Lee J; Lee SH; Lee SH; Lee SS; Lee SW; Lee YA; Nah SS; Park SH; Sheen DH; Shim SC; Gyu Song G; Suh CH; Uhm WS; Yoo DH; Yoo WH; Yoon BY; Bae SC
    Semin Arthritis Rheum; 2012 Jun; 41(6):745-51. PubMed ID: 22154221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis.
    Lee JH; Sung YK; Choi CB; Cho SK; Bang SY; Choe JY; Hong SJ; Jun JB; Kim TH; Lee J; Lee HS; Yoo DH; Yoon BY; Bae SC
    BMC Musculoskelet Disord; 2016 Feb; 17():98. PubMed ID: 26912147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
    Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
    Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
    Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
    J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with the Use of Complementary and Alternative Medicine for Korean Patients with Rheumatoid Arthritis.
    Han M; Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Jung YO; Kim SK; Kim TH; Koh E; Lee HS; Lee J; Lee JH; Lee SS; Nah SS; Shim SC; Yoo DH; Yoo WH; Yoon BY; Jee SH; Bae SC
    J Rheumatol; 2015 Nov; 42(11):2075-81. PubMed ID: 26329343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.
    Iannaccone CK; Lee YC; Cui J; Frits ML; Glass RJ; Plenge RM; Solomon DH; Weinblatt ME; Shadick NA
    Rheumatology (Oxford); 2011 Jan; 50(1):40-6. PubMed ID: 20847201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
    Raaschou P; Simard JF; Neovius M; Askling J;
    Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis.
    Nilsson AC; Christensen AF; Junker P; Lindegaard HM
    Dan Med Bull; 2011 Apr; 58(4):A4257. PubMed ID: 21466765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
    Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Early Rheumatoid Arthritis Treatment Evaluation Registry (ERATER) in the United States.
    Sokka T; Pincus T
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S178-81. PubMed ID: 16273804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.
    Verstappen SM; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Holmqvist M; Horne L; Lampl K; Michaud K; Nyberg F; Pappas DA; Reed G; Symmons DP; Tanaka E; Tran TN; Yamanaka H; Ho M
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1637-45. PubMed ID: 26201948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of a rheumatoid arthritis records-based index of severity.
    Ting G; Schneeweiss S; Katz JN; Weinblatt ME; Cabral D; Scranton RE; Solomon DH
    J Rheumatol; 2005 Sep; 32(9):1679-87. PubMed ID: 16142860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis.
    Shin S; Park EH; Kang EH; Lee YJ; Song YW; Ha YJ
    Joint Bone Spine; 2021 May; 88(3):105124. PubMed ID: 33346105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.
    Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1399-406. PubMed ID: 20506121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.